Synthesis, Crystal Structures, and Antimicrobial and Antitumor Studies of Two Zinc(II) Complexes with Pyridine Thiazole Derivatives

Table 10

Tests of IC₅₀ (μg/mL) of the ligands and complexes against cancer cells^a.

Compounds	IC50 ± SD (μg·mL^−1)
	A549^b	BT-20^b	MCF-7^b	U20S^b
L1	30.16 ± 3.45	45.30 ± 4.84	26.50 ± 4.49	52.00 ± 4.37
L2	36.72 ± 2.36	23.25 ± 1.63	21.33 ± 3.81	38.22 ± 4.12
1	7.43 ± 1.55	12.23 ± 2.11	17.35 ± 3.23	9.78 ± 1.24
2	4.48 ± 0.68	8.23 ± 1.02	6.38 ± 0.29	9.52 ± 0.93

^aResults are expressed as the half maximal inhibitory concentration (IC₅₀). ^bHuman lung cancer cells (A549), human breast cancer cells (BT-20), human ovarian cancer cells (MCF-7), human osteosarcoma cells (U20S).